| Literature DB >> 32117729 |
Jung Oh Kim1, Hak Hoon Jun2, Eo Jin Kim3, Jeong Yong Lee1, Han Sung Park1, Chang Soo Ryu1, Seungki Kim2, Doyeun Oh4, Jong Woo Kim2, Nam Keun Kim1.
Abstract
In colorectal carcinogenesis, the unique molecular and genetic changes that occur within cells result in specific CRC phenotypes. The involvement of the long non-coding RNA, HOTAIR, in cancer development, progression, and metastasis is well-established. Various studies have reported on the contribution of HOTAIR to cancer pathogenesis. Therefore, we selected four HOTAIR polymorphisms (rs7958904G>C, rs1899663G>T, rs4759314A>G, and rs920778T>C) to evaluate the association of each variant with CRC prevalence and prognosis. We conducted a case-control study of 850 individuals to identify the genotype frequencies of each polymorphism. The study population included 450 CRC patients and 400 control individuals that were randomly selected following a health screening. Notably, rs7958904 and rs1899663, their hetero genotype, and the dominant model were significantly different when compared to the healthy control group (rs7958904; AOR = 1.392, 95% CI = 1.052-1.843, P = 0.021). To evaluate the effect of HOTAIR polymorphisms on the survival rate, we analyzed patient mortality and relapse occurrence within 3 and 5 years with Cox-regression analysis. The rs7958904 CC polymorphism mortality rate was significantly higher than the GG polymorphism mortality rate (adjusted HR = 2.995, 95% CI = 1.189-7.542, P = 0.021). In addition, the rs920778 CC genotype was significantly different than the TT genotype (adjusted HR = 3.639, 95% CI = 1.435-9.230, P = 0.007). In addition, this study confirmed that genetic variants of HOTAIR alter the mRNA expression level (P < 0.01). We suggest that HOTAIR rs7958904G>C which is associated with CRC prevalence and mortality is a potential biomarker for CRC. The association between HOTAIR gene polymorphisms and CRC prevalence were reported for the first time.Entities:
Keywords: HOTAIR; case-control study; colorectal cancer; long non-coding RNA; single nucleotide polymorphisms
Year: 2020 PMID: 32117729 PMCID: PMC7020018 DOI: 10.3389/fonc.2020.00072
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Baseline characteristics between CRC patients and healthy control subjects.
| Male, | 173 (41.6) | 214 (45.1) | 0.317 | 122 (44.9) | 0.443 | 84 (44.4) | 0.568 |
| Age (mean ± SD) | 61.2 ± 11.38 | 62.1 ± 12.48 | 0.230 | 61.9 ± 12.97 | 0.267 | 62.1 ± 11.81 | 0.344 |
| HTN, n (%) | 168 (40.4) | 157 (33.1) | 0.030 | 86 (31.6) | 0.025 | 68 (36) | 0.347 |
| DM, n (%) | 55 (13.2) | 76 (16.0) | 0.277 | 46 (16.9) | 0.220 | 30 (15.9) | <0.0001 |
| Folate (mean ± SD) | 9.0 ± 8.05 | 7.8 ± 6.82 | <0.0001 | 7.9 ± 6.77 | <0.0001 | 7.7 ± 6.97 | <0.0001 |
| Hcy (mean ± SD) | 9.8 ± 4.25 | 10.7 ± 7.8 | 0.330 | 10.4 ± 8.12 | 0.870 | 10.9 ± 7.34 | 0.096 |
| TNM stage | |||||||
| I | 45 (9.5) | 20 (7.4) | 24 (12.7) | ||||
| II | 188 (39.7) | 115 (42.3) | 70 (37) | ||||
| III | 189 (39.9) | 109 (40.1) | 78 (41.3) | ||||
| IV | 46 (9.7) | 27 (9.9) | 16 (8.5) | ||||
| Tumor size | |||||||
| T < 5 cm | 275 (58) | 176 (64.7) | 96 (50.8) | ||||
| T ≥ 5 cm | 187 (39.5) | 92 (33.8) | 93 (49.2) |
CRC, colorectal cancer; SD, standard deviation; HTN, hypertension; DM, diabetes mellitus; Hcy, plasma homocysteine; TNM, tumor node metastasis.
P-values were calculated using chi-squared tests for categorical data and two–sided t-tests for continuous data.
Comparison of HOTAIR polymorphism genotype frequencies between CRC patients and healthy controls.
| GG | 249 (59.9) | 244 (51.5) | 1.000 (reference) | 151 (55.5) | 1.000 (reference) | 89 (47.1) | 1.000 (reference) | |||
| GC | 140 (33.7) | 191 (40.3) | 1.352 (1.014–1.801) | 0.040 | 102 (37.5) | 1.202 (0.859–1.681) | 0.283 | 84 (44.4) | 1.559 (1.076–2.258) | 0.019 |
| CC | 27 (6.5) | 39 (8.2) | 1.399 (0.802–2.443) | 0.237 | 19 (7) | 1.364 (0.7–2.66) | 0.362 | 16 (8.5) | 1.516 (0.751–3.062) | 0.246 |
| Dominant | 1.351 (1.027–1.777) | 0.032 | 1.206 (0.875–1.663) | 0.252 | 1.547 (1.085–2.205) | 0.016 | ||||
| Recessive | 1.168 (0.681–2.002) | 0.573 | 1.144 (0.602–2.175) | 0.682 | 1.235 (0.626–2.435) | 0.543 | ||||
| HWE- | 0.230 | 0.850 | 0.755 | 0.538 | ||||||
| GG | 271 (65.1) | 264 (55.7) | 1.000 (reference) | 161 (59.2) | 1.000 (reference) | 101 (53.4) | 1.000 (reference) | |||
| GT | 132 (31.7) | 186 (39.2) | 1.338 (1.004–1.784) | 0.047 | 100 (36.8) | 1.219 (0.871–1.707) | 0.248 | 76 (40.2) | 1.404 (0.968–2.038) | 0.074 |
| TT | 13 (3.1) | 24 (5.1) | 1.783 (0.86–3.698) | 0.120 | 11 (4) | 1.608 (0.671–3.854) | 0.287 | 12 (6.3) | 2.141 (0.906–5.06) | 0.083 |
| Dominant | 1.378 (1.043–1.822) | 0.024 | 1.244 (0.897–1.725) | 0.191 | 1.481 (1.035–2.12) | 0.032 | ||||
| Recessive | 1.559 (0.764–3.182) | 0.223 | 1.387 (0.591–3.256) | 0.452 | 1.958 (0.849–4.515) | 0.115 | ||||
| HWE- | 0.523 | 0.228 | 0.350 | 0.646 | ||||||
| AA | 358 (86.1) | 395 (83.3) | 1.000 (reference) | 229 (84.2) | 1.000 (reference) | 159 (84.1) | 1.000 (reference) | |||
| AG | 55 (13.2) | 71 (15) | 1.062 (0.717–1.574) | 0.763 | 39 (14.3) | 1.031 (0.651–1.632) | 0.898 | 28 (14.8) | 1.026 (0.611–1.721) | 0.924 |
| GG | 3 (0.7) | 8 (1.7) | 1.017 (0.201–5.139) | 0.984 | 4 (1.5) | 0.622 (0.063–6.126) | 0.684 | 2 (1.1) | 1.722 (0.28–10.577) | 0.557 |
| Dominant | 1.059 (0.721–1.557) | 0.770 | 1.012 (0.644–1.591) | 0.960 | 1.056 (0.639–1.746) | 0.831 | ||||
| Recessive | 0.994 (0.197–5.016) | 0.994 | 0.62 (0.063–6.091) | 0.682 | 1.658 (0.27–10.172) | 0.585 | ||||
| HWE- | 0.581 | 0.027 | 0.130 | 0.545 | ||||||
| TT | 241 (57.9) | 258 (54.4) | 1.000 (reference) | 149 (54.8) | 1.000 (reference) | 102 (54) | 1.000 (reference) | |||
| TC | 149 (35.8) | 180 (38) | 1.115 (0.838–1.484) | 0.457 | 103 (37.9) | 1.152 (0.825–1.607) | 0.407 | 73 (38.6) | 1.075 (0.74–1.56) | 0.706 |
| CC | 26 (6.3) | 36 (7.6) | 1.222 (0.699–2.135) | 0.482 | 20 (7.4) | 1.353 (0.704–2.599) | 0.365 | 14 (7.4) | 1.118 (0.54–2.317) | 0.763 |
| Dominant | 1.124 (0.855–1.477) | 0.402 | 1.167 (0.849–1.604) | 0.342 | 1.076 (0.754–1.535) | 0.688 | ||||
| Recessive | 1.139 (0.661–1.962) | 0.640 | 1.228 (0.653–2.307) | 0.524 | 1.058 (0.519–2.159) | 0.876 | ||||
| HWE- | 0.645 | 0.555 | 0.706 | 0.851 | ||||||
CRC, colorectal cancer; AOR, adjusted odds ratio; 95% CI, 95% confidence interval.
Adjusted by age, gender, HTN, DM.
HOTAIR polymorphism genotype frequencies and CRC patient 3-years mortality in overall, colon, and rectum cancer.
| GG | 244 (51.5) | 40 (54.1) | 1.000 (reference) | 151 (55.5) | 27 (62.8) | 1.000 (reference) | 89 (47.1) | 11 (37.9) | 1.000 (reference) | |||
| GC | 191 (40.3) | 27 (36.5) | 0.891 (0.501–1.584) | 0.695 | 102 (37.5) | 13 (30.2) | 0.659 (0.299–1.452) | 0.304 | 84 (44.4) | 14 (48.3) | 1.797 (0.704–4.582) | 0.222 |
| CC | 39 (8.2) | 7 (9.5) | 2.995 (1.189–7.542) | 0.021 | 19 (7) | 3 (7) | 4.835 (1.094–21.376) | 0.039 | 16 (8.5) | 4 (13.8) | 6.076 (1.125–32.814) | 0.037 |
| Dominant | 1.070 (0.633–1.810) | 0.801 | 0.820 (0.401–1.675) | 0.587 | 2.039 (0.850–4.892) | 0.112 | ||||||
| Recessive | 2.583 (1.086–6.145) | 0.033 | 3.208 (0.877–11.738) | 0.080 | 3.383 (0.893–12.818) | 0.075 | ||||||
| GG | 264 (55.7) | 45 (60.8) | 1.000 (reference) | 161 (59.2) | 29 (67.4) | 101 (53.4) | 15 (51.7) | 1.000 (reference) | ||||
| GT | 186 (39.2) | 23 (31.1) | 0.732 (0.401–1.336) | 0.312 | 100 (36.8) | 11 (25.6) | 0.499 (0.216–1.152) | 0.105 | 76 (40.2) | 11 (37.9) | 1.606 (0.619–4.171) | 0.333 |
| TT | 24 (5.1) | 6 (8.1) | 2.328 (0.876–6.185) | 0.092 | 11 (4) | 3 (7) | 4.507 (1.167–17.413) | 0.030 | 12 (6.3) | 3 (10.3) | 7.110 (0.831–60.815) | 0.075 |
| Dominant | 0.874 (0.508–1.503) | 0.627 | 0.691 (0.331–1.443) | 0.327 | 1.592 (0.668–3.792) | 0.296 | ||||||
| Recessive | 2.227 (0.871–5.693) | 0.096 | 4.468 (1.263–15.812) | 0.021 | 1.576 (0.316–7.866) | 0.581 | ||||||
| AA | 395 (83.3) | 61 (82.4) | 1.000 (reference) | 229 (84.2) | 37 (86) | 159 (84.1) | 23 (79.3) | 1.000 (reference) | ||||
| AG | 71 (15) | 13 (17.6) | 1.102 (0.555–2.188) | 0.782 | 39 (14.3) | 6 (14) | 0.739 (0.276–1.979) | 0.549 | 28 (14.8) | 6 (20.7) | 1.462 (0.471–4.539) | 0.513 |
| GG | 8 (1.7) | 0 (0) | N/A | 0.991 | 4 (1.5) | 0 | N/A | 0.991 | 2 (1.1) | 0 | N/A | 0.990 |
| Dominant | 1.007 (0.507–1.997) | 0.985 | 0.694 (0.262–1.840) | 0.465 | 1.265 (0.406–3.938) | 0.687 | ||||||
| Recessive | N/A | 0.967 | N/A | 0.967 | N/A | 0.990 | ||||||
| TT | 258 (54.4) | 44 (59.5) | 1.000 (reference) | 149 (54.8) | 27 (62.8) | 102 (54) | 15 (51.7) | 1.000 (reference) | ||||
| TC | 180 (38) | 22 (29.7) | 0.754 (0.410–1.385) | 0.365 | 103 (37.9) | 12 (27.9) | 0.683 (0.310–1.505) | 0.347 | 73 (38.6) | 10 (34.5) | 1.208 (0.438–3.334) | 0.717 |
| CC | 36 (7.6) | 8 (10.8) | 3.639 (1.435–9.230) | 0.007 | 20 (7.4) | 4 (9.3) | 12.964 (2.216–75.858) | 0.005 | 14 (7.4) | 4 (13.8) | 3.925 (0.860–17.908) | 0.079 |
| Dominant | 0.985 (0.570–1.700) | 0.956 | 0.901 (0.440–1.844) | 0.776 | 1.493 (0.611–3.648) | 0.382 | ||||||
| Recessive | 3.481 (1.456–8.324) | 0.005 | 8.143 (1.946–34.084) | 0.004 | 3.383 (0.893–12.818) | 0.075 | ||||||
Adjusted for age, sex, hypertension, diabetes mellitus, tumor size, lymph node metastasis, chemotherapy, smoking, and alcohol based on Cox-regression analysis.
Figure 1Survival plot from a Cox proportiona hazards model with HOTAIR rs7958904G>C and rs920778T>C polymorphisms in colorectal cancer (CRC). Survival curve of patients grouped by 3 years mortality in colorectal cancer based on (A) HORAIR rs7958904GG vs. HOTAIR rs7958904CC genotypes (B) HORAIR rs920778TT vs. HOTAIR rs920778CC genotypes. HR, hazard ratio.
Figure 2The effects of HOTAIR rs7958904 G>C and rs1899663 variant on colorectal cancer (CRC) risk modulated by clinical factors. (A) The synergic effect for CRC susceptibility combined between HOTAIR rs7958904 GC+CC and low plasma folate group (AOR, 3.191) than rs7958904 GC+CC with high plasma folate group (AOR, 1.285) or rs7958904 GG with low plasma folate group (AOR, 2.545). (B) The HOTAIR rs1899663 G>T were show to elevated CRC prevalence, in the case of HOTAIR rs1988663 GT+TT with low plasma folate group (AOR, 3.196) than rs1988663 GT+TT with high plasma folate group (AOR, 1.353) or rs1899663 GG with low plasma folate group (AOR, 2.601).